{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:41:17Z","timestamp":1791060077678,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6429,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1093\/annonc\/mdf155","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T23:00:51Z","timestamp":1027724451000},"page":"928-943","source":"Crossref","is-referenced-by-count":119,"title":["Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study"],"prefix":"10.1016","volume":"13","author":[{"given":"T.","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Murate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Uike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1093\/annonc\/mdf155_bb0010","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1997.15.2.445","article-title":"High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bierman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.1993.11.4.644","article-title":"Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy","volume":"11","author":"Dana","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","article-title":"Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdf155_bb0030","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","article-title":"Mantle cell lymphoma: An entity comes of age","volume":"87","author":"Weisenburger","year":"1996","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0035","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"a clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0040","first-page":"2253","article-title":"Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma","volume":"95","author":"Yatabe","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0045","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V92.4.1184","article-title":"Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin\u2019s lymphoma without eradicating the malignant clone","volume":"92","author":"Davis","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0050","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131: anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0055","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clinical Cancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0060","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0065","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0070","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0075","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0080","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0085","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0095","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1349-7006.1998.tb03280.x","article-title":"Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody","volume":"89","author":"Taji","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nature Med"},{"key":"10.1093\/annonc\/mdf155_bb0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdf155_bb0115","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European\u2013American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0120","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas: summary and description of a Working Formulation for clinical usage","volume":"49","author":"Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project","year":"1982","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf155_bb0125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma. A Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0130","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdf155_bb0135","first-page":"1215","article-title":"Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen","volume":"136","author":"Mason","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdf155_bb0140","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0145","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1349-7006.1994.tb02969.x","article-title":"Monoclonal antibody against PRAD1\/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus","volume":"85","author":"Banno","year":"1994","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0150","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1349-7006.1994.tb02940.x","article-title":"Immunohistochemical analysis on the cyclin D1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma","volume":"85","author":"Nakamura","year":"1994","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0155","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","article-title":"Toxicity grading criteria of the Japan Clinical Oncology Group (JCOG)","volume":"23","author":"Tobinai","year":"1993","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1023\/A:1008332713631","article-title":"Response criteria for NHL: importance of normal lymphnode size and correlation with response rates","volume":"11","author":"Grillo-Lopez","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [B]"},{"key":"10.1093\/annonc\/mdf155_bb0170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdf155_bb0175","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/annonc\/mdf155_bb0180","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"a predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdf155_bb0185","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.1994.12.7.1343","article-title":"Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma","volume":"12","author":"Lopez-Guillermo","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0190","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V86.4.1460.bloodjournal8641460","article-title":"International Prognostic Index for aggressive non-Hodgkin\u2019s lymphoma is valid for all malignancy grades","volume":"86","author":"Hermans","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0195","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.2000.01965.x","article-title":"A UK muticenter phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma with PCR monitoring of molecular response","volume":"109","author":"Foran","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdf155_bb0200","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0205","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0210","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","article-title":"Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model","volume":"9","author":"Romaguera","year":"1991","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdf155_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/2.suppl_2.123","article-title":"Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years","volume":"2","author":"Bastion","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0220","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/0277-5379(91)90425-D","article-title":"Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients","volume":"27","author":"Soubeyran","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf155_bb0225","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: Prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0230","first-page":"1921","article-title":"Low-grade non-Hodgkin\u2019s lymphoma in northern Norway: treatment, outcome and prognostic factors","volume":"18","author":"Bremnes","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0235","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","article-title":"Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma","volume":"15","author":"Wendum","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0240","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V93.9.3081","article-title":"Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma","volume":"93","author":"Lopez-Guillermo","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/10428199609045721","article-title":"Prolonged survival in follicular non-Hodgkin\u2019s lymphoma is predicted by achievement of complete remission with initial treatment: results of a long-term study with multivariate analysis of prognostic factors","volume":"24","author":"Davidge-Pitts","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdf155_bb0250","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.jjco.a023262","article-title":"Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan","volume":"26","author":"Katsumata","year":"1996","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdf155_bb0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/8.suppl_1.S49","article-title":"Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III\u2013IV patients","volume":"8","author":"Foussard","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","article-title":"IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients","volume":"62","author":"Nguyen","year":"1999","journal-title":"Eur J Hematol"},{"key":"10.1093\/annonc\/mdf155_bb0270","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0275","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdf155_bb0280","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0285","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","article-title":"Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic","volume":"22","author":"Iacona","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1093\/annonc\/mdf155_bb0290","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0046-8177(83)80299-8","article-title":"Lymphoproliferative diseases in Japan and western countries: Proceedings of the United State\u2014Japan seminar, September 6 and 7, 1982, in Seattle, Washington","volume":"14","author":"Kadin","year":"1983","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdf155_bb0295","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/0277-5379(89)90361-1","article-title":"Non-Hodgkin\u2019s lymphoma of follicular center cell type in Osaka, Japan","volume":"25","author":"Ohsawa","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1093\/annonc\/mdf155_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3835(98)00278-X","article-title":"B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification","volume":"135","author":"Ohshima","year":"1999","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdf155_bb0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1349-7006.2000.tb00952.x","article-title":"Practical utility of the revised European\u2013American classification of lymphoid neoplasms for Japanese non-Hodgkin\u2019s lymphomas","volume":"91","author":"Izumo","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf155_bb0310","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hon.2900070305","article-title":"Malignant lymphoma in Hawaii\u2013Japanese: a retrospective morphologic survey","volume":"7","author":"Yanagihara","year":"1989","journal-title":"Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419634812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419634812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/6\/928\/587609\/mdf155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T11:49:46Z","timestamp":1733658586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419634812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S0923753419634812"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf155","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}